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Abstract The growing interest in the molecular
subclassification of colorectal cancers is increasingly
facilitated by large multicenter biobanking initiatives.
The quality of tissue sampling is pivotal for successful
translational research. This study shows the quality of
fresh frozen tissue sampling within a multicenter
cohort study for colorectal cancer (CRC) patients.
Each of the seven participating hospitals randomly
contributed ten tissue samples, which were collected
following Standard Operating Procedures (SOP)
using established techniques. To indicate if the amount
of intact RNA is sufficient for molecular discovery
research and prove SOP compliance, the RNA
integrity number (RIN) was determined. Samples with
a RIN\ 6 were measured a second time and when
consistently low a third time. The highest RIN was
used for further analysis. 91% of the tissue samples
had a RIN C 6 (91%). The remaining six samples had
a RIN between 5 and 6 (4.5%) or lower than 5 (4.5%).
The median overall RIN was 7.3 (range 2.9–9.0). The
median RIN of samples in the university hospital
homing the biobank was 7.7 and the median RIN for
the teaching hospitals was 7.3, ranging from 6.5 to 7.8.
No differences were found in the outcome of different
hospitals (p = 0.39). This study shows that the
collection of high quality fresh frozen samples of
colorectal cancers is feasible in a multicenter design
with complete SOP adherence. Thus, using basic
sampling techniques large patient cohorts can be
organized for predictive and prognostic (bio)marker
research for CRC.
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Introduction
Colorectal cancer (CRC) is the second most common
malignancy in the Western World (DeSantis et al.
2014). As in all cancer research, there is a strong trend
towards molecular subclassification of CRC (Guinney
et al. 2015). The studies conducted to identify these
molecular and clinically relevant markers demand
large numbers of patients with accurate long-term
clinical data combined with high quality tissue
samples to be able to use state of the art techniques
(Riegman et al. 2007, 2008). Subsequently, the
standard enclosed formalin-fixed paraffin-embedded
tissue can be used to develop assays for daily clinical
practice. Therefore, large multicenter biobanking
initiatives are needed to facilitate these research
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efforts (Burbach et al. 2016; Rose 2016). However,
10% of the fresh frozen tissue samples collected for
research purposes are unsuitable for molecular anal-
yses. This is due to multiple non-modifiable factors
such as tissue type, intrinsic patient factors, warm
ischemia time (extraction of the resection specimen
after ligation of the large vessels) and modifiable
factors such as cold ischemia time (tissue transport
from the operating theatre to the pathology lab), the
conservation (fixation/stabilization) method, subse-
quent transport and the storage of the tissue samples
(Boudou-Rouquette et al. 2010; Qualman et al. 2004).
The RNA Integrity Number (RIN), first described in
2006, is currently a common standard used to assess
tissue quality (Schroeder et al. 2006). This method
became well accepted to measure the SOP adherence
of quality in tissue banking (Morente et al. 2006).
The current study assessed the tissue quality of the
MATCH study, a multicenter cohort study in the
region of Rotterdam, the Netherlands, enrolling
patients with CRC and obtaining fresh frozen tissue
samples in one university hospital with experience in
tissue sampling and storage by dedicated personnel,
and in six non-university teaching hospitals that are
not used to nor standardly equipped and staffed for
routine fresh frozen tissue sampling.
Materials and methods
MATCH-study design
The MATCH-study is an ongoing multicenter cohort
study including adult patients with CRC undergoing
curative surgery. The participating centers include one
university hospital (Erasmus University Medical
Center) and six non-university teaching hospitals
(Elisabeth-Tweesteden hospital, IJsselland hospital,
Ikazia hospital, Maasstad hospital, Reinier de Graaf
Hospital, Franciscus Gasthuis). The MATCH study
was approved by the Medical Ethical Board of the
Erasmus University Medical Center, Rotterdam, the
Netherlands (MEC-2007-088). All patients provide
written informed consent for the collection of long-
term clinical data and storage of tissue samples. The
study is an integrated approach using clinical patient
care in non-university hospitals with university-based
facilities for tissue and data storage. The rationale of
this study was to identify subtypes of colorectal
cancer, related prognostic markers and outcome of
treatment. Liver metastases was defined as primary
outcome defining a good or dismal outcome of disease
progression as liver involvement has been demon-
strated to be the main factor to determine long term
outcome.
Clinical data
Medical specialists of departments of Surgery, Pathol-
ogy, Gastroenterology, Radiology and Medical oncol-
ogy were consulted. Clinical data included reports of
colonoscopy, radiology and pathology, as well as
surgical reports and postoperative complications. A
standard case record was created in a web based
multicenter access database. The follow-up of these
patients was standardized in all hospitals following an
intensive follow-up schedule according the national
CRC guidelines (Lochhead et al. 2013).
Tissue sampling
All tissue samples were handled following a Standard
Operation Procedure (SOP) provided by the study
team at the start of the study. In short, resection
specimens were transported (at room temperature
without any conservation fluids) from the operating
theatre to the pathology department, immediately
following removal of the specimen from the patient.
At the pathology department the specimen was
handled at room temperature and within two hours
after resection samples were snap-frozen as described
below. When the 2 h time limit was exceeded, no
tissue samples were taken.
Macroscopically, one to four tumor samples and
one to two healthy colon tissue samples of 0.5–1 cm3
were taken by the pathologist. Tissue sampling for the
MATCH study was not allowed to interfere with the
standard pathology routine needed for clinical prac-
tice. Tumor and normal tissue were stored in labeled
cryovials and snap frozen in liquid nitrogen or dry-ice
(Mager et al. 2007). Samples were then stored at low-
temperature refrigerators (-80 C) in the hospital of
primary surgery and in batches transported to the
central tissue bank (-196 C liquid nitrogen barrels)
at the university hospital. Of all new tissue specimens
stored in the central bank, on a yearly base 2% is tested
for quality, by determining the RNA integrity (Chi
et al. 2016; Morente et al. 2006).
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Tissue quality assessment
To assess the tissue quality of the samples collected in
the MATCH-study, we randomly selected 10 tissue
samples per participating hospital, representing about
4% of the entire collection. Samples that were exposed
to neoadjuvant chemotherapy and/or radiotherapy
were excluded as this may damage tissue resulting in
failure of analysis.
RNA quality was determined by measuring of the
RIN (Schisterman et al. 2008; Schroeder et al.
2006). For RNA isolation, 10–20 tissue slides of
10 lm were cut. One slide was colored by hema-
toxylin and eosin (H&E) stain for morphological
confirmation of the diagnosis. For RNA extraction,
the slides were put in a Qiazol Lysis buffer and
shaken for ten seconds to homogenize the tissue.
RNA was then extracted using the miRNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the
method suggested by the manufacturer. The integ-
rity of RNA was measured by the Bioanalyser
(Agilent Technologies, Santa Clara, CA, USA)
using the lab-on-a-chip, RNA 6000 nano assay.
This is an automated system based on elec-
trophoretic separation. The RIN is directly calcu-
lated by applying an algorithm on the ratio of 18S/
28S ribosomal RNA bands. A tissue sample with a
RIN of C 6 is believed to be of good quality
(Fig. 1a) (Strand et al. 2007). Samples with a
RIN\ 6 (Fig. 1b) were measured a second and if
consistently low a third time. When the RIN was
still low, the case was discussed with the technician
to see if any deviation from protocol (e.g. during
the freezing procedure or sample preparation) could
explain the low RIN. When samples were measured
multiple times, the highest RIN was used for further
analysis.
Statistical analysis
Statistical analyses was performed using SPSS (IBM
Corp. Released 2012. IBM SPSS Statistics for Win-
dows, Version 21.0. Armonk, NY: IBM Corp.).
Categorical date were described as frequencies with
percentages and continuous data as median with the
range. The Chi square test was used to compare
categorical data, for continuous date the One-way
ANOVA test was used. A p value less than 0.05 was
considered to be statistically significant.
Results
In total, 70 random samples were selected for analysis
out of the 1700 samples collected in the study period
1st October 2007–1st January 2013. During the work-
up and data quality check, three samples were
excluded leaving a total sample size of n = 67. Two
tissue samples were exposed to neoadjuvant radiation
therapy and one tissue sample was too small.
Out of the 67 samples, two samples were analyzed
two times (3.0%) and seven samples three times
(10.4%). The median overall RIN of all samples was
7.3 (range 2.9–9.0). The majority (n = 61) of the
Fig. 1 a Image intact RNA (RIN 9.0), obtained from the
electropherogram and virtual gel. b Image partially degraded
RNA (RIN 3.3), obtained from the electropherogram and virtual
gel
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tissue samples had a RIN C 6 (91%). The remaining
six samples had a RIN between 5 and 6 (4.5%) or
lower than 5 (4.5%) (Figs. 2, 3). Three of the seven
samples that were measured three times had a
RIN\ 5 and were discussed with the technician.
However, the low RIN could not be attributed to
protocol deviations. The median RIN for a center
specialized in tissue sampling (university hospital)
was 7.7 and the median RIN for teaching hospitals
without a wide experience in this field ranged from 6.5
to 7.8 (Table 1). The overall median RIN of the non-
university teaching hospitals (median RIN = 7.3) did
not differ significantly with the median RIN of the
university hospital (p = 0.39) (Fig. 4). When using
the specialized university hospital as a reference, the
median RIN of one non specialized teaching hospital
(hospital 6) had a significantly lower median RIN than
the university hospital (p = 0.02). However, a median
RIN of 6.5 is still well above the cut-off of 6.
Interestingly, the range of RIN for the non-university
teaching hospitals tended to be larger than the range of
RIN if the university hospital (Fig. 3).
Discussion
This study shows that the collection of high quality
fresh frozen samples of CRC is feasible in a
multicenter design including hospitals for which fresh
frozen tissue sampling is not part of the daily routine.
In our study, 91% had a RIN C 6 and thus can be used
for highly demanding gene array assays.
The RIN was developed and published in 2006 to
meet the need for a reliable standard to estimate the
integrity of RNA samples (Schroeder et al. 2006). A
comparison study comparing a subjective evaluation
of the electropherogram, the 28S–18S peaks ratio and
the RIN showed a superior result for the manual and
RINmethod over the ratio method (Strand et al. 2007).
Nowadays, the RIN is widely used to quantify the
RNA quality of samples and select samples for
expression analyses. However, the cut-off used to
select ‘high quality’ samples varies in literature,
ranging from a RIN of 5–7. These cut-offs can be
based on the recommendations in a manufacturer
manual or on the experience of a lab (Asterand 2006;
Bao et al. 2013; Hong et al. 2010; Viana et al. 2013).
At our hospital, we use a RIN of C6 as the cut-off
which qualified 91% of the samples as high quality
samples. When samples repeatedly have a RIN\ 6,
they may be excluded to prevent a transcript specific
bias, or analytical or bioinformatics steps specifically
dealing with the low quality samples should be
included in the methodology (Lauss et al. 2007;
Viljoen et al. 2013). Furthermore, samples with a
RIN\ 6 can still be used for RT-qPCR applications in
which only short amplicons are analyzed.
Fig. 2 The RIN
distribution in 67 samples
Fig. 3 Box plot with the RIN per hospital
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The quality of RNA expression in tissue samples is
dependent on multiple factors such as tissue type,
intrinsic patient factors, warm and cold ischemia time,
thefixationmethodand the storage of the tissue samples.
While tissue type and intrinsic patient factors cannot be
modified, other factors (i.e. ischemia time, fixation
method and the storage of samples) can be influenced.
The RIN can be used to determine large influences
during the pre-analytical phase. Smaller differences can
be assessed based onRNAexpression analyses (Gallego
Romero et al. 2014). For fresh frozen samples, the most
important factor appears to be the ischemia time and
freeze thawing effects after freezing. A recent review
specifically addressing the effect of cold ischemia on
RNA stability concluded that in most studies only
minimal changes in the RIN were observed (B10%)
during a cold ischemia times of 1–6 h (Grizzle et al.
2016). One outlier reported a significantly decreased
RIN of 44% in samples with a cold ischemia time of
1.5 h compared to samples with a cold ischemia time of
10 min (Hong et al. 2010). However, the 28S:18S ratios
did not significantly differ (Hong et al. 2010). Impor-
tantly, the definition of cold ischemia time differed
between studies and often the cold ischemia time in the
operating theatre was not taken into account. Further-
more, the effects of warm ischemia time are often
ignored while they most likely interact with the effects
of cold ischemia time. Thismay be explained by the fact
that this factor is hard to reliably score and is considered
to be a non-modifiable factor since attempts tominimize
warm ischemia time may affect patient care. Such non-
modifiable influences can only be documented to obtain
a tool for determination of this influence (Riegman et al.
2015). Although we did not specifically assessed the
association between ischemia time and the RIN in our
study, the maximum cold ischemia time was 2 h since
this was included in the SOP. Thus, the high percentage
of high quality samples in our study is in line with the
current literature. For the few samples with consistently
low RIN values, no protocol deviations were found
suggesting the low RIN was caused by non-modifiable
factors.
Our study shows that SOP compliance was positive
in all the cooperating hospitals and high quality fresh
frozen tissue sampling is possible in a multicenter
setting including both university and non-university
hospitals. These findings support the feasibility of
emerging large-scale ‘fit-for-purpose’ biobanks to
facilitate the increasingly complex field of fundamen-
tal and translational cancer research (Burbach et al.
2016; Kap et al. 2014; Rose 2016).
In conclusion, our study shows that the collection of
high quality fresh frozen samples of CRC is feasible in
a multicenter design and using basic sampling tech-
niques. Thus, large patient cohorts can be organized
for predictive and prognostic (bio)marker research for
CRC.
Fig. 4 Box plot with the RIN for the university hospital and
non-university hospitals
Table 1 Median RNA
integrity number per
hospital
Hospital Number of samples Median RIN Range p value
1: University hospital 10 7.7 6.8–9 0.391
2 9 7.3 5.9–8.1
3 10 7.2 4.3–8.2
4 10 7.8 5.8–8.7
5 10 7.4 3.3–8.7
6 9 6.5 6–7.8
7 9 7.5 2.9–8.1
All samples 67 7.3 2.9–9
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